Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.

Click here to learn how we are responding.

Menu

Close

Sign InSign Out
ProductsOrderOrder

See all
Co-pay cards & patient savings offers
MaterialsSamples*
Hospital products*Vaccines, biologics & small-molecule medicines**​​​​​​​​​​​​​​​​​​​​​
Patient AssistancePatient Assistance

Find available assistance programsGo to Patient Assistance
Pfizer Oncology Together
Pfizer RxPathways
Explore contentExplore content
 
Explore more content
EventsVideosMaterials
ContactContact

See all Contact
Pfizer corporateAsk a question

Menu

Close

    AboutAbout

    About ATTR-CMMOD/MOAStudy Design
    DosingEfficacy & SafetySavings & SupportSavings & SupportEventsVideosMaterialsAccess & Patient Support
  • Prescribing Information
  • Patient Information
  • Patient Site
  • Medical Information

  • VYNDAMAX® (tafamidis)

    Efficacy and safety profile

    Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam

    Learn more

    Dosing

    Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam

    Learn more

    Study design

    Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam

    Learn more

    VYNDAMAX is proven to
    reduce all-cause mortality and
    CV-related hospitalization

    Learn more

    VYNDAMAX resources

    Explore ATTR-CM events, videos and materials

    Learn more

    Access

    VyndaLinkTM connects patients with support

    Learn more

    Identify ATTR-CM

    Red flags and early diagnosis

    Learn more


    VYNDAMAX® AND VYNDAQEL® are registered trademarks of Pfizer Inc.

    Adverse Reactions

    In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.

    Specific Populations

    Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.

    Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.

    VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
    ​​​​​​​
    Please see Full Prescribing Information including Patient Information.

      INDICATION AND LIMITATIONS OF USE

      VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
      ​​​​​​​
      Please see Full Prescribing Information including Patient Information.